Zobrazeno 1 - 10
of 112
pro vyhledávání: ''
Autor:
Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Patrick Leo, Pingfu Fu, Paula Toro, Amy Joehlin-Price, Mojgan Mokhtari, Haider Mahdi, Anant Madabhushi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundWe present a computational approach (ArcTIL) for quantitative characterization of the architecture of tumor-infiltrating lymphocytes (TILs) and their interplay with cancer cells from digitized H&E-stained histology whole slide images and ev
Autor:
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Martin J Edelman, John V Heymach, Ramaswamy Govindan, Carlos Bachier, Bernard Doger de Spéville, Matthew J Frigault, Anthony J Olszanski, Vincent K Lam, Natalie Hyland, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry Batrakou, Melissa M Pentony, Joseph P Sanderson, Andrew Gerry, Diane Marks, Jane Bai, Tom Holdich, Elliot Norry, Paula M Fracasso
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting
Autor:
Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundCombination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian canc
Autor:
Pashtoon Murtaza Kasi, Griffin Budde, Michael Krainock, Vasily N Aushev, Allyson Koyen Malashevich, Meenakshi Malhotra, Perry Olshan, Paul R Billings, Alexey Aleshin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treat
Autor:
Ying Jing, Xue Chen, Kunyan Li, Yaoming Liu, Zhao Zhang, Yiqing Chen, Yuan Liu, Yushu Wang, Steven H Lin, Lixia Diao, Jing Wang, Yanyan Lou, Douglas B Johnson, Xiang Chen, Hong Liu, Leng Han
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundTo determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies.MethodsThe retrospective analysis includes clinical information f
Autor:
Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastati
Autor:
Xiu Nie, Junli Liu, Kaixiong Tao, Tao Zhang, Lan Zhang, Gang Li, Zhiguo Hou, Zheng Wang, Ming Cai, Gang Wu, Chuanqing Wu, Tao Liu, Zhenyu Lin, Linfang Wang, Jun Fan, Hongli Liu, Peng Zhang, Xin Li, Jing Wang, Jingbo Gao, Kunyu Yang, Chi Ma, Kailin Cai, Weikang Zhang
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundIn locally advanced rectal cancer (LARC), preoperative short-course radiotherapy (SCRT) with delayed surgery has been shown to be as effective as long-course chemoradiotherapy, with only modest benefits. This study aimed to evaluate the eff
Autor:
Shihai Zhao, Luoyan Ai, Yuan Ji, Qing Liu, Xiaoshi Jin, Jie Gao, Yimei Wang, Yiyi Yu, Jingjie Li, Qian Li, Tianshu Liu, Yuehong Cui, Duojiao Wu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
The use of immune checkpoint inhibitors (ICIs) is rising exponentially in numerous cancers, but immune-related adverse events can occur. We report a rare case of high-grade drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome develo
Autor:
Antony Tin, Lillian L. Siu, Nickolas Attanasio, David P. Goldstein, Tina Shek, Bayardo Perez-Ordonez, J. Javier Díaz-Mejía, Ronald Shazer, Anna Spreafico, Douglas B. Chepeha, Ben X Wang, Ilan Weinreb, Hirak Der-Torossian, Andrew Hope, Aaron R. Hansen, Daniel Vilarim Araujo, Qingyan Au, Amy Prawira, John R. de Almeida, Alexey Aleshin, Jordan Feeney, Marc Oliva, Peter Olson, Stephen M. Smith, Jonathan C. Irish, Jeff Bruce, Anthony Fortuna, Himanshu Sethi, Isan Chen, Trevor J. Pugh, Dax Torti, Scott V. Bratman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic ant
Autor:
Sonali Jindal, Hong Chen, Christopher J. Logothetis, Ana Aparicio, Rebecca S. S. Tidwell, Paul G. Corn, Padmanee Sharma, Bilal A. Siddiqui, Ashwin Varma, James P. Allison, Sumit K. Subudhi, Shalini S. Yadav, Sreyashi Basu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundImmune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein